429 related articles for article (PubMed ID: 18930662)
1. Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis.
Segal B; Rhodus NL; Patel K
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Dec; 106(6):778-87. PubMed ID: 18930662
[TBL] [Abstract][Full Text] [Related]
2. [Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers].
Benucci M; Turchini S; Parrochi P; Boccaccini P; Manetti R; Cammelli E; Manfredi M
Recenti Prog Med; 2006 Mar; 97(3):134-9. PubMed ID: 16700418
[TBL] [Abstract][Full Text] [Related]
3. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
4. Differentiating the efficacy of tumor necrosis factor inhibitors.
Haraoui B
J Rheumatol Suppl; 2005 Mar; 74():3-7. PubMed ID: 15742457
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.
Bombardieri S; Ruiz AA; Fardellone P; Geusens P; McKenna F; Unnebrink K; Oezer U; Kary S; Kupper H; Burmester GR;
Rheumatology (Oxford); 2007 Jul; 46(7):1191-9. PubMed ID: 17504821
[TBL] [Abstract][Full Text] [Related]
6. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
7. [Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs].
Bombardieri S; Ferraccioli G; Ferri C; Galeazzi M; Lapadula G; Cerinic MM; Montecucco C; Triolo G; Trotta F; Valentini G
Reumatismo; 2009; 61 Suppl 1():1-23. PubMed ID: 19999184
[TBL] [Abstract][Full Text] [Related]
8. Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors.
Iannone F; Gremese E; Atzeni F; Biasi D; Botsios C; Cipriani P; Ferri C; Foschi V; Galeazzi M; Gerli R; Giardina A; Marchesoni A; Salaffi F; Ziglioli T; Lapadula G;
J Rheumatol; 2012 Jun; 39(6):1179-84. PubMed ID: 22467933
[TBL] [Abstract][Full Text] [Related]
9. [Paradigm shift in the treatment of rheumatoid arthritis by biologics].
Tanaka Y
Rinsho Byori; 2008 Apr; 56(4):309-15. PubMed ID: 18516965
[TBL] [Abstract][Full Text] [Related]
10. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept.
Jamnitski A; Bartelds GM; Nurmohamed MT; van Schouwenburg PA; van Schaardenburg D; Stapel SO; Dijkmans BA; Aarden L; Wolbink GJ
Ann Rheum Dis; 2011 Feb; 70(2):284-8. PubMed ID: 21068090
[TBL] [Abstract][Full Text] [Related]
11. [Inhibition of the joint destruction in RA by TNF-blocking agents].
Kameda H
Clin Calcium; 2007 Apr; 17(4):553-60. PubMed ID: 17404485
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].
Tijhuis GJ; van de Putte LB; Breedveld FC
Ned Tijdschr Geneeskd; 2001 Sep; 145(39):1880-5. PubMed ID: 11605312
[TBL] [Abstract][Full Text] [Related]
13. Which TNF inhibitor for rheumatoid arthritis?
Med Lett Drugs Ther; 2010 May; 52(1338):38-9. PubMed ID: 20467356
[No Abstract] [Full Text] [Related]
14. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
[TBL] [Abstract][Full Text] [Related]
15. [Review of the protective effects of tumor necrosis factor inhibitors in rheumatoid arthritis].
Finckh A; Gabay C; Guerne PA
Rev Med Suisse Romande; 2004 Sep; 124(9):547-50. PubMed ID: 15552748
[TBL] [Abstract][Full Text] [Related]
16. Anti-TNF-alpha therapies: they are all the same (aren't they?).
Mpofu S; Fatima F; Moots RJ
Rheumatology (Oxford); 2005 Mar; 44(3):271-3. PubMed ID: 15561736
[No Abstract] [Full Text] [Related]
17. A new era in rheumatoid arthritis treatment.
Costello JC; Halverson PB
WMJ; 2003; 102(7):29-33. PubMed ID: 14711021
[TBL] [Abstract][Full Text] [Related]
18. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
[TBL] [Abstract][Full Text] [Related]
19. Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data.
Wu E; Chen L; Birnbaum H; Yang E; Cifaldi M
Curr Med Res Opin; 2007 Aug; 23(8):1749-59. PubMed ID: 17588306
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor inactivation in the management of rheumatoid arthritis.
Baumgartner SW
South Med J; 2000 Aug; 93(8):753-9. PubMed ID: 10963503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
